Srikripa Devarakonda
Stock Analyst at Truist Securities
(1.80)
# 3,124
Out of 4,876 analysts
63
Total ratings
30.51%
Success rate
-7.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Hold | $72 → $73 | $68.37 | +6.77% | 10 | May 27, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $21 → $11 | $7.54 | +45.89% | 1 | May 5, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $975 → $940 | $521.00 | +80.42% | 7 | Apr 30, 2025 | |
| BIIB Biogen | Maintains: Buy | $210 → $199 | $126.08 | +57.84% | 4 | Apr 29, 2025 | |
| KROS Keros Therapeutics | Maintains: Buy | $43 → $25 | $13.49 | +85.32% | 5 | Apr 9, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $60 → $76 | $55.69 | +36.47% | 2 | Mar 11, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,029 → $1,038 | $775.45 | +33.86% | 4 | Feb 3, 2025 | |
| ABBV AbbVie | Maintains: Buy | $211 → $217 | $182.31 | +19.03% | 3 | Feb 3, 2025 | |
| PFE Pfizer | Maintains: Buy | $36 → $32 | $24.19 | +32.29% | 1 | Dec 18, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $33 → $50 | $13.17 | +279.65% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $45 | $35.81 | +25.66% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $54 → $53 | $44.12 | +20.13% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.81 | +2,883.43% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $4.15 | +261.45% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $11.64 | +209.28% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $33.16 | +111.10% | 4 | May 29, 2024 |
Incyte
May 27, 2025
Maintains: Hold
Price Target: $72 → $73
Current: $68.37
Upside: +6.77%
Arvinas
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $7.54
Upside: +45.89%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Buy
Price Target: $975 → $940
Current: $521.00
Upside: +80.42%
Biogen
Apr 29, 2025
Maintains: Buy
Price Target: $210 → $199
Current: $126.08
Upside: +57.84%
Keros Therapeutics
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $13.49
Upside: +85.32%
Protagonist Therapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $60 → $76
Current: $55.69
Upside: +36.47%
Eli Lilly and Company
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $775.45
Upside: +33.86%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $182.31
Upside: +19.03%
Pfizer
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $24.19
Upside: +32.29%
Edgewise Therapeutics
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $13.17
Upside: +279.65%
Nov 25, 2024
Maintains: Buy
Price Target: $36 → $45
Current: $35.81
Upside: +25.66%
Nov 1, 2024
Reiterates: Buy
Price Target: $54 → $53
Current: $44.12
Upside: +20.13%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.81
Upside: +2,883.43%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $4.15
Upside: +261.45%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $11.64
Upside: +209.28%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $33.16
Upside: +111.10%